Pavan Mallikarjun

Pavan Mallikarjun

Auto-generated profile, based on publicly available information

Pavan Mallikarjun

Institute for Mental Health, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
AGAngharad Gregory
Angharad Gregory
PMPavan Mallikarjun
Pavan Mallikarjun
RURachel Upthegrove
Rachel Upthegrove
Background: Depression in schizophrenia predicts poor outcomes, including suicide, yet the effectiveness of antidepressants for its treatment remains uncertain.Aims: To synthesise the evidence of the effectiveness of antidepressants for the treatment of depression in schizophrenia.Method: Multiple databases Were searched and inclusion Criteria included participants aged over 18 years with schizophrenia or related psychosis with a depressive episode. Papers were quality assessed used the Cochrane risk bias tool. Meta-analyses were performed for risk difference and standardised mean difference of all antidepressants, antidepressant class and individual antidepressant where sufficient studies allowed.Results: A total of 26 moderate- to low-quality trials met inclusion criteria. In meta-analysis a significant risk difference was found in favour of antidepressant treatment, with a number needed to treat of 5 (95% CI 4–9). Studies using tools specifically designed to assess depression in schizophrenia showed a larger effect size. However, after sensitivity analysis standardised mean difference of all antidepressants did not show a statistically significant improvement in depression score at end-point, neither did any individual antidepressant class.Conclusions: Antidepressants may be effective for the treatment of depression in schizophrenia, however, the evidence is mixed and conclusions must be qualified by the small number of low- or moderate-quality studies. Further sufficiently powered, high-quality studies are needed.

1 May 2011 in Biological Psychiatry
Verified
Journal Article
Closed access
LENA PALANIYAPPANLENA PALANIYAPPAN
LENA PALANIYAPPAN
PMPavan Mallikarjun
Pavan Mallikarjun
VJVerghese Joseph
Verghese Joseph
TWThomas P. White
Thomas P. White
PLPeter F. Liddle
Peter F. Liddle

13 December 2010 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
LENA PALANIYAPPANLENA PALANIYAPPAN
LENA PALANIYAPPAN
PMP. Mallikarjun
P. Mallikarjun
VJV. Joseph
V. Joseph
TWT. P. White
T. P. White
PLP. F. Liddle
P. F. Liddle
Background: An intrinsic cerebral network comprising the anterior cingulate and anterior insula (the salience network) is considered to play an important role in salience detection in healthy volunteers. Aberrant salience has been proposed as an important mechanism in the production of psychotic symptoms such as delusions and hallucinations (reality distortion). We investigated whether structural deficits in the salience network are associated with the reality distortion seen in schizophrenia.Method: A sample of 57 patients in a clinically stable state of schizophrenia and 41 controls were studied with high-resolution magnetic resonance imaging.Results: Bilateral volume reduction was seen in the anterior cingulate and anterior insula in patients with schizophrenia. Reduced volume in the two left-sided regions of the salience network was significantly correlated with the severity of reality distortion.Conclusions: These findings suggest that a deficit of grey matter in the salience network leads to an impaired attribution of salience to stimuli that is associated with delusions and hallucinations in schizophrenia.

27 March 2018 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
PMPavan Kumar Mallikarjun
Pavan Kumar Mallikarjun
PLParis Alexandros Lalousis
Paris Alexandros Lalousis
TDThomas Frederick Dunne
Thomas Frederick Dunne
KHKareen Heinze
Kareen Heinze
RRRenate Lep Reniers
Renate Lep Reniers
RURachel Upthegrove
Rachel Upthegrove
Auditory verbal hallucinations (AVH) often lead to distress and functional disability, and are frequently associated with psychotic illness. Previously both state and trait magnetic resonance imaging (MRI) studies of AVH have identified activity in brain regions involving auditory processing, language, memory and areas of default mode network (DMN) and salience network (SN). Current evidence is clouded by research mainly in participants on long-term medication, with chronic illness and by choice of seed regions made ‘a priori’. Thus, the aim of this study was to elucidate the intrinsic functional connectivity in patients presenting with first episode psychosis (FEP). Resting state functional MRI data were available from 18 FEP patients, 9 of whom also experienced AVH of sufficient duration in the scanner and had symptom capture functional MRI (sc fMRI), together with 18 healthy controls. Symptom capture results were used to accurately identify specific brain regions active during AVH; including the superior temporal cortex, insula, precuneus, posterior cingulate and parahippocampal complex. Using these as seed regions, patients with FEP and AVH showed increased resting sb-FC between parts of the SN and the DMN and between the SN and the cerebellum, but reduced sb-FC between the claustrum and the insula, compared to healthy controls.It is possible that aberrant activity within the DMN and SN complex may be directly linked to impaired salience appraisal of internal activity and AVH generation. Furthermore, decreased intrinsic functional connectivity between the claustrum and the insula may lead to compensatory over activity in parts of the auditory network including areas involved in DMN, auditory processing, language and memory, potentially related to the complex and individual content of AVH when they occur.

24 February 2018 in The Gerontologist
Verified
Journal Article
Open access
PDF file
MHMichael D Hopkinson
Michael D Hopkinson
JRJames Reavell
James Reavell
DLDeirdre A Lane
Deirdre A Lane
PMPavan Mallikarjun
Pavan Mallikarjun
There is limited evidence for the efficacy of cognitive behavioral therapy (CBT) in managing psychological morbidities in caregivers of dementia patients. To evaluate changes in dementia caregivers’ depression, anxiety, and stress following CBT. Also to assess quality of life, intervention adherence/satisfaction and therapy effectiveness using different formats, frequencies, and delivery methods. Studies were identified through electronic bibliographic searches (MEDLINE, EMBASE, CINAHL, PsycINFO, and the Cochrane Library) and from gray literature (Conference Proceedings Citation Index and clinicaltrials.gov). Data were pooled for meta-analysis. Twenty-five studies were included. Depression (standardized mean difference [SMD] = −0.34; 95% confidence interval [CI] −0.47 to −0.21; p < .001) and stress (SMD = −0.36; 95% CI: −0.52 to −0.20; p < .001) were significantly reduced after CBT, relative to comparator groups, while anxiety was not (SMD = 0.10; 95% CI: −0.18 to 0.39; p = .47). A subgroup analysis demonstrated that statistically significant reductions in depression and stress were limited to group, but not individual, formats. An additional subgroup analysis revealed that eight CBT sessions or fewer were equally effective as more than eight sessions at significantly reducing depression and stress, relative to comparator groups. Furthermore, analysis with independent samples t-tests demonstrated no statistically significant differences between mean changes in depression (MD = 0.79; 95% CI: −0.45 to 2.03; p = .21) and stress (MD = 0.21; 95% CI: −1.43 to 1.85; p = .80) when directly comparing CBT groups of ≤8 and >8 sessions. Group CBT provides small but significant benefits to caregivers’ depression and stress. Therapy cost-effectiveness may be improved by limiting therapy to group formats and eight sessions.

15 March 2023 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
Isabel Morales-MuñozIsabel Morales-Muñoz
Isabel Morales-Muñoz
PMPavan K. Mallikarjun
Pavan K. Mallikarjun
JCJoht S. Chandan
Joht S. Chandan
RTRasiah Thayakaran
Rasiah Thayakaran
RURachel Upthegrove
Rachel Upthegrove
SMSteven Marwaha
Steven Marwaha
Background: Little is still known about the long-term impact of childhood and adolescent persistent depression and anxiety in adulthood.Aims: To investigate the impact of persistent anxiety, depression, and comorbid anxiety and depression across childhood and adolescence on the development of multiple adverse outcomes in young adulthood.Method: This study used data from 8122 participants in the Avon Longitudinal Study of Parents and Children cohort. The Development and Well-Being Assessment (DAWBA) examined child anxiety and depression symptomatology. The DAWBA generalised anxiety and mood subscales at 8, 10 and 13 years were selected, and a measure of comorbid anxiety and depression symptoms was created at each time point. Further, several mental and physical health, substance misuse and education/employment problems were assessed at 24 years. Latent class growth analyses were used to detect trajectories of anxiety, depression and comorbid anxiety and depression; and logistic regression to examine how persistent anxiety, depression or both were associated with adverse outcomes at 24 years.Results: All three classes with persistent anxiety, depression or both were significantly associated with presenting with any mental health problems and any education/employment problem. Persistent high levels of depression and high levels of comorbid anxiety and depression, but not persistent high anxiety, were significantly associated with any physical health problem. High levels of comorbid anxiety and depression was the only DAWBA domain significantly associated with substance misuse; and overall, this was the domain that exerted the greatest negative impact, as it presented the highest odd ratio values.Conclusions: Children and adolescents with comorbid anxiety and depression are at the highest risk for having more adverse outcomes at 24 years.